Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Noemi Maliziola
Observed names:
Maliziola, Noemi,
N. Maliziola
Institutions:
Università Cattolica del Sacro Cuore,
Agostino Gemelli University Polyclinic,
Istituti di Ricovero e Cura a Carattere Scientifico
Observed institutions:
Università Cattolica del Sacro Cuore,
Agostino Gemelli University Polyclinic,
Istituti di Ricovero e Cura a Carattere Scientifico
ORCID:
0009-0009-1310-6115
Observed ORCID:
0009-0009-1310-6115
OpenAlex ID:
A5012595694
Accessible model predicts response in hormone receptor positive HER2 negative breast cancer receiving neoadjuvant chemotherapy
2025
·
Luca Mastrantoni
, Giovanna Garufi
, et al.
·
npj Breast Cancer
·
12
PDF
Adjuvant denosumab in early breast cancer: a systematic review and meta-analysis of randomized controlled clinical trials
2023
·
Luca Mastrantoni
, Giovanna Garufi
, et al.
·
Therapeutic Advances in Medical Oncology
·
12
PDF
Activity and Efficacy of Neoadjuvant Chemotherapy in Luminal-HER2 Negative Early Breast Cancer According to HER2 Score (Low vs. Score 0): A Retrospective Study
2025
·
Giovanna Garufi
, Luca Mastrantoni
, et al.
·
Clinical Breast Cancer
·
6
PDF
Artificial intelligence (AI) –based machine learning models (ML) for predicting pathological complete response (pCR) in patients with hormone receptor (HoR) –positive/HER2-negative early breast cancer (EBC) undergoing neoadjuvant chemotherapy (NCT): A retrospective cohort study.
2023
·
Luca Mastrantoni
, Giovanna Garufi
, et al.
·
Journal of Clinical Oncology
·
5
PDF
Predicting progression-free survival in hormone-receptor positive (HR+/HER2–) metastatic breast cancer (MBC) treated with CDK4/6 inhibitors: A machine learning approach
2026
·
Sergio Pannunzio
, Luca Mastrantoni
, et al.
·
The Breast
·
4
PDF
Bone Health and Endocrine Therapy with Ovarian Function Suppression in Premenopausal Early Breast Cancer: A Real-Life Monocenter Experience with Denosumab
2025
·
Angelachiara Rotondi
, Valentina Frescura
, et al.
·
Current Oncology
·
4
PDF
Comparison of machine learning and deep learning models for survival prediction in early-stage hormone receptor-positive/HER2-negative breast cancer receiving neoadjuvant chemotherapy
2025
·
L. Mastrantoni
, G. Garufi
, et al.
·
ESMO Real World Data and Digital Oncology
·
3
PDF
Next Frontier in HER2+/HR+ Breast Cancer: Leveraging Cell Cycle Control with CDK4/6 Inhibitors
2026
·
Ilaria Poli
, Gaia Rachele Oliva
, et al.
·
Journal of Personalized Medicine
·
2
PDF
Abstract PO2-01-14: Development of Artificial Intelligence-based Machine Learning Models for Predicting Survival In Hormone-Receptor-Positive/HER2-Negative Early Breast Cancer undergoing Neoadjuvant Chemotherapy
2024
·
Luca Mastrantoni
, Giovanna Garufi
, et al.
·
Cancer Research
·
1
276P Development and external validation of an artificial intelligence (AI)-based machine learning model (ML) for predicting pathological complete response (pCR) in hormone-receptor (HoR)-positive/HER2-negative early breast cancer (EBC) undergoing neoadjuvant chemotherapy (NCT)
2023
·
L. Mastrantoni
, G. Garufi
, et al.
·
Annals of Oncology
·
1
PDF
138P Activity and efficacy of neoadjuvant chemotherapy (NACT) in luminal-HER2-negative early breast cancer (EBC) according to HER2 score (low vs score 0): A retrospective study
2023
·
G. Garufi
, L. Carbognin
, et al.
·
ESMO Open
·
1
PDF
Survival outcomes of neoadjuvant versus adjuvant chemotherapy in stage II-III hormone receptor-positive/HER2-negative breast cancer: A propensity score–matched analysis.
2026
·
Armando Orlandi
, Francesca Salvatori
, et al.
·
Journal of Clinical Oncology
16P Trastuzumab deruxtecan (T-Dxd) in metastatic HER2-positive breast cancer: Early circulating tumor DNA (ctDNA) responses detected by comprehensive genomic profiling
2026
·
A. Fabi
, E. De Paolis
, et al.
·
ESMO Open
PDF
516P Gradient boosting machine (GBM) for predicting progression-free survival (PFS) in hormone-receptor positive (HR+) metastatic breast cancer (mBC) receiving upfront CDK4/6 inhibitors (CDK4/6i)
2025
·
S. Pannunzio
, L. Mastrantoni
, et al.
·
Annals of Oncology
Abstract P1-11-18: Detrimental effect on survival of neoadjuvant (NACT) versus adjuvant (ACT) chemotherapy in stage II-III hormone receptor-positive & HER2-neg (HR+/HER2-) breast cancer: A propensity score-matched (PSM) analysis of a retrospective patient series
2025
·
Armando Orlandi
, Giorgia Arcuri
, et al.
·
Clinical Cancer Research
236P Bone health (BH) and endocrine therapy (ET) in premenopausal early breast cancer (eBC): A real-life monocenter experience with denosumab
2025
·
A. Rotondi
, V. Frescura
, et al.
·
ESMO Open
254P Development of machine learning models for the prediction of early progression (EP) to first-line (1L) cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) therapy in oestrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC)
2024
·
S. Pannunzio
, L. Mastrantoni
, et al.
·
ESMO Open
Abstract P2-02-06: Adjuvant Denosumab treatment in early breast cancer: a systematic review and meta-analysis of randomized controlled clinical trials
2023
·
Luca Mastrantoni
, Giovanna Garufi
, et al.
·
Cancer Research
Show more works
View as search
Works count:
20
Citation count:
51
H-index:
4
I10-index:
2
Year
Topic
Type